Clinical response in metastatic castration-resistant prostate cancer (mCRPC) cases treated with supra-physiological doses of testosterone: Bipolar androgen therapy.
Senji HoshiVladimir BilimKiyotsugu HoshiTakuya NakagawaSadanobu SatoRie SakagamiMasato KonnoTakashi KudoKenji NumahataIsoji SasagawaPublished in: Clinical case reports (2022)
Androgen deprivation therapy is a standard of care for metastatic prostate cancer. A paradoxical approach utilizing high doses of testosterone in castration-resistant prostate cancer patients demonstrated clinical responses. Here, we report on four heavily pretreated Japanese patients (including one patient on hemodialysis) successfully treated with supra-physiological doses of testosterone.
Keyphrases
- end stage renal disease
- prostate cancer
- replacement therapy
- chronic kidney disease
- peritoneal dialysis
- squamous cell carcinoma
- small cell lung cancer
- newly diagnosed
- ejection fraction
- healthcare
- palliative care
- prognostic factors
- quality improvement
- case report
- smoking cessation
- mesenchymal stem cells
- cell therapy
- health insurance